SpringWorks Therapeutics, Inc. (SWTX) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18
	10-K	10-K	10-K	10-K	10-K
Total revenues [+]	0.0	0.0	35.0	3.5	0.7
Net investment income				3.5	0.7
Revenue growth		-100.0%	886.7%	423.2%
Cost of goods sold	0.0	0.0	0.0	3.5	0.7
Gross profit	0.0	0.0	35.0	0.0	0.0
Gross margin			100.0%	0.0%	0.0%
Selling, general and administrative [+]	134.6	71.8	29.5	16.7	8.6
General and administrative	134.6	71.8	29.5	16.7	8.6
Research and development	146.1	101.7	51.9	42.5	9.9
Equity in earnings	-2.9	-1.0	-0.6	-2.6
EBITDA [+]	-282.8	-174.0	-46.6	-61.7	-18.5
EBITDA growth	62.6%	273.5%	-24.5%	233.8%
EBITDA margin			-133.1%	-1738.4%	-2724.8%
Depreciation and amortization	0.8	0.5	0.3	0.2	0.0
EBIT [+]	-283.6	-174.5	-46.9	-61.9	-18.5
EBIT growth	62.5%	271.7%	-24.1%	234.5%
EBIT margin			-134.1%	-1743.8%	-2727.3%
Interest income	6.3	0.7	1.3
Interest income	6.3	0.7	1.3
Other income (expense), net [+]	-0.1	-0.2	0.0	3.5	0.7
Other	-0.1	-0.2	0.0
Pre-tax income	-277.4	-173.9	-45.6	-58.3	-17.8
Income taxes	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-277.4	-173.9	-45.6	-50.6	-17.8
Net margin			-130.2%	-1425.9%	-2627.3%

Basic EPS [+]	($5.21)	($3.59)	($1.05)	($3.81)
Growth	45.2%	240.7%	-72.4%
Diluted EPS [+]	($5.21)	($3.59)	($1.05)	($3.81)
Growth	45.2%	240.7%	-72.4%

Shares outstanding (basic) [+]	53.3	48.5	43.3	13.3
Growth	9.9%	12.0%	226.2%
Shares outstanding (diluted) [+]	53.3	48.5	43.3	13.3
Growth	9.9%	12.0%	226.2%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.